Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) insider Riad Mishlawi bought 736 shares of Hikma Pharmaceuticals stock in a transaction dated Tuesday, May 7th. The stock was acquired at an average cost of GBX 1,979 ($24.86) per share, for a total transaction of £14,565.44 ($18,298.29).
Hikma Pharmaceuticals Stock Performance
Shares of Hikma Pharmaceuticals stock opened at GBX 1,981 ($24.89) on Friday. Hikma Pharmaceuticals PLC has a 1 year low of GBX 1,711 ($21.49) and a 1 year high of GBX 2,222 ($27.91). The firm's 50-day moving average is GBX 1,878.02 and its 200 day moving average is GBX 1,863.84. The stock has a market cap of £4.40 billion, a price-to-earnings ratio of 2,913.24, a PEG ratio of 2.38 and a beta of 0.44. The company has a debt-to-equity ratio of 53.92, a current ratio of 1.57 and a quick ratio of 1.27.
Hikma Pharmaceuticals Increases Dividend
The company also recently declared a dividend, which was paid on Friday, May 3rd. Stockholders of record on Thursday, March 21st were issued a dividend of $0.47 per share. This is a boost from Hikma Pharmaceuticals's previous dividend of $0.25. The ex-dividend date was Thursday, March 21st. This represents a dividend yield of 1.86%. Hikma Pharmaceuticals's dividend payout ratio is presently 8,382.35%.
Analyst Ratings Changes
HIK has been the topic of several research reports. Berenberg Bank reissued a "hold" rating and set a GBX 2,000 ($25.13) price objective on shares of Hikma Pharmaceuticals in a research note on Thursday, April 25th. Barclays reiterated an "equal weight" rating and set a GBX 2,000 ($25.13) target price on shares of Hikma Pharmaceuticals in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of GBX 2,068.75 ($25.99).
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
From Priority Gold | Ad
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
Click here for your free guide
Check Out Our Latest Stock Analysis on Hikma Pharmaceuticals
About Hikma Pharmaceuticals
(
Get Free Report)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
